OCR Text |
Show Cerebral Perfusion Imaging Ellen G. Hoeffner, MD Abstract: There are multiple imaging techniques available review the currently available perfusion imaging techniques to assess cerebral perfusion, including positron emission with an emphasis on PWI and PCT, the techniques most tomography ( PET), xenon computed tomography ( XeCT), often used in current clinical practice ( Table 1). single photon emission computed tomography ( SPECT), perfusion- weighted MRI ( PWI), and perfusion computed tomography ( PCT). Current interest has focused mainly on DYNAMTC PERFUSION CT their use in the setting of acute , ,, ° .. x. . b, r a. i n. isct he, m . ia. Per, f usion D^ ynami. c P_ C,_ T_ stxu d, i. e s are owb tai. n ed, , b y moni. t ori. n g itth e imaging may be able to distinguish rnfarcted from salvage- „ 2 . . ,. t , , , , , , , , , , , . , • . • •, , T. o • first pass of an lodrnated contrast agent through the cerebral able ischemic tissue as a guide to treatment. Perfusion , „_ , . , , „ , • .. /• ^ . , . , , , , ° . . , . . , . vasculature ( 4,6). Changes in tissue attenuation that occur techniques may also be helpful in cases of chronic ischemia, • ,, , • « ^ 7 , • • ,- w, A r, . . ... , , in the brain after the contrast miection are measured ( 1,4,6). post- subarachnoid hemorrhage vasospasm, trauma, and con- _, . Al _,_,„ , A „ Al ^. ' ; , , , , , .. .-, , • Post- processing of the PCT data allows the generation of templated therapeutic carotid artery occlusion. , , , ? • ^ • , • , , color- coded maps of various perfusion parameters, mclud- (/ Neuro- Ophthalmol 2005; 25: 313- 320) ing cerebral blood flow ( CBF), cerebral blood volume ( CBV), mean transit time ( MTT), and the time- to- peak ( TTP), the A time from the start of contrast agent injection to the time variety of imaging techniques have been available to of m a x i m u m e n h a n c e m e n t ( l j 2 j 7 > 8 ) . T h e m a p s g e n e r a t ed assess cerebral perfusion since the 1970s, beginning , , ., , • ., , • ., • e., . . > & & depend on the algorithm used m the processing of the per-with positron emission tomography ( PET) and xenon fi • CT d i ( 4 6\ computed tomography ( XeCT). Over the next two decades, „ . . ,' , • ,• . , ., . T) r, rF , U1 . f ° . . , , ' Recent studies have indicated that PCT may be able single photon emission computed tomography ( SPECT), . ,• .. • , ,, , •, , • , • , tor r cr^ v ^> to distinguish reversible from non- reversible ischemia by perfusion- weighted MRI ( PWI), and perfusion CT ( PCT) • ... .. ,- • . , F . . . . , . „ r • assessing quantitative perfusion parameter values or gener-were introduced into the armamentarium of perfusion .• e u A • e * • * u *• / F atrng maps of penumbra and infarct core using the quanti-lmagmg techniques ( 1). These techniques have been used to . .• , . , • , r, / « m\ TT, i « * u A , ° . /.. . . ,. , tative data and special software ( 9,10). The latter method evaluate a variety of disease states, including acute and ., . ^ OXI , e U1 • , . • • , • ,- , , •, , assumes that as CBF decreases, areas of reversible ischemia chronic ischemia, ischemia from post- subarachnoid hem- •„ , , . • , r* r>\ r u e * N , r , . , will have normal to increased CBV because of autoregu-orrhage ( SAH) vasospasm, head trauma, and m the assess- , . ,-, . .• , e • U1 • e ° „ v . . . , . ., , . latory vasodilatation, whereas areas of irreversible rnfarc-ment of patients requiring therapeutic carotid occlusion ^ ^ haye d e c r e a s e d C B Y Thus> l o w C B V a r e a s m ay ( 1,2). The advent of thrombolytic therapy to treat acute be c o m p a r a b l e t o r e s t r i c t e d d i f f u s i o n a r e a s o n d i f f u s i o n. stroke has intensified the interest in perfusion imaging • , . , • , . • ,, A^ T> T/ I im r> u r • •*• i . . . . . . . . r . weighted images obtained by MRI ( 1,10). Results of initial techniques in an attempt to distinguish already rnfarcted . ,• ^ .• . , r. ... .• ., , ,, e ^ . r . b . studies attempting to define quantitative thresholds for areas tissue from ischemic but potentially salvageable tissue ( the e U1 • , , • U1 • e .• • A- . . \ . . „ \- ° i reversible ischemia and irreversible infarction indicate ischemic penumbra) ( 3- 5). Such imaging may allow for ^ ^ s i m i k r tQ f h o s e o b t a i n e d w i f h Q t h e r p e r f o s i o n ^ better selection of patients for thrombolytic therapy with modalities s u c h a s P E T and XeCT ( 11,12) ( Fig. 1). thehopeofrmprovedoutcomesandfewercomphcations. lt „ ^ A- u u *• A * I, , „ ,- , , • However, no studies have been performed assessing the may also allow expansion of the current therapeutic ,-,-. fT> r ™ * •. .. u 1 ^- * u A- ** U . , „ , ^ , , „ . r . , ability of PCT to guide thrombolytic therapy or predict the thAwRiosa2iedsn0fADoiuf9donredGel, oeop d r, wg@ ar prey1r It slC5, um asoU0m se0ifcngmni ociatvEh r3nioer. ane . erfs ds hotRipu tgoMoay eudn otinedroofdse lMin ocagcaficeyolct , hri CtU ivogeI ananVEitnvtoel e lHrrera nseDniv a( tdtlyrG t- i hv P. o e6fSAH, M y/ oA) Nhs eit nocefv(, fnhmu n1 i eN/ gr,) A rs. aU , n rnbT MfHioo, vh rDer, i. a r s, sMl r tiDhtnIya etS r4prHty8aai. osc 1r- tst, a0elmp em9rie tt;, aen wAlEtn Bii.- amo„ ml2llf ail: rmtoloIioet• lsca n rihkciplgyg , a l ee euosCvrm sf ftTae* yb oiu• Tirsvhea s se oauee eib, sdo n mrs0( dina ef1lueoil a s ,3sTs rpspte, ri) eP 1( rroachd,^ ee4iesrna j, srFer) i g sfe. rn, om u u• e b c sc rcrIcie0aon. oo tu fvl nh. ntlria, aejams seusr t * rp cetnan oturrcnuoha ellt, ymtari- sl no r sm aiucnmrp• ciier anaarbswecitlte , on aiu irsuelatitvleynanhanet^ its titdn snai i, o sn nne/ nbg, dwa ( pa slr1 , iia co ct) chnt, eoah.\ i e aote nd ars, rn e zc mtmbo, afs,_ lerarl oa waeolwi mlntni C it tdahilraBd( i u . im1c eFntSh5o i c. t) rtrw.. neo. eh e nodniag, toIril. uh_ fc -- l a- a resultant increase in CBV ( 15). Paired CBF measurements maximally vasodilated and cannot respond further to acet-before and after a vasodilatory stimulus, such as acetazol- azolamide ( 15). CBF values in these regions will not increase amide, can provide information about the presence of appropriately. There may even be a decrease in CBF in the autoregulatory vasodilation and impaired reserve vaso- affected territory after acetazolamide injection as vasodila-dilatory capacity. Acetazolamide normally causes vasodila- tion in other well- perfused brain territories diverts blood tation and an increase in CBF by at least 25% ( 16). But away from fully vasodilated poorly perfused regions ( 17). vascular territories under hemodynamic stress are already Improvement in PCT parameters after stenting or bypass has been demonstrated in case reports ( 13,14), but there are no with this technique, typically a 10 to 30 mm thick section, data on whether PCT can predict which patients are at higher usually at the level of the basal ganglia, which limits risk of stroke or will benefit from revascularization. Studies visualization to portions of the anterior, middle, and poste-of the use of PCT in patients with vasospasm after SAH and rior cerebral artery territories ( 1,2,8). PCT may be contra-those undergoing carotid balloon test occlusion ( BTO) are in indicated in patients with contrast allergies or renal failure; preliminary stages ( 18,19) ( Fig. 2). the high injection rates require the use of a large- bore IV PCT is a rapid technique requiring approximately catheter, which may cause patient discomfort. 1 minute of scanning time and several minutes to obtain post- processed perfusion maps. It can potentially be widely PERFUSION- WEIGHTED MRI available, requiring only a helical CT scanner and appro- The most commonly used MR perfusion technique, priate software ( 1,2). Other CT examinations, such as a is dynamic susceptibility contrast ( DSC) imaging. It is non- contrast CT scan and CT angiography ( CTA), can be similar to PCT in that a contrast agent ( a gadolinium che-obtained in the same setting. However, there are significant late) is injected intravenously that causes changes in the MR concerns regarding the accuracy and reproducibility of the signal as the agent passes through the vasculature. The change quantitative values obtained with this technique ( 1). For in signal intensity is then measured and perfusion maps are example, only a limited area of the brain can be imaged generated most commonly CBF, CBV, TTP, or MTT PWI is usually performed in conjunction with PWI has had limited use in other clinical settings, diffusion- weighted MRI ( DWI) and assessment of apparent There are some published reports describing its use in diffusion coefficient ( ADC) values. This combination of assessing patients with chronic cerebrovascular disease, techniques can differentiate ischemic from infarcted tissue including with acetazolamide challenge to evaluate cerebro-and predict the death of ischemic tissue if reperfusion does vascular reserve ( 29- 32). The use of PWI in evaluating not occur ( 1,20- 22). In one report, ( 23) these techniques patients with post- SAH vasospasm and during carotid BTO were used to guide intra- arterial thrombolytic therapy. Areas has also been limited ( 33,34). of abnormal diffusion are usually assumed to represent DWI and PWI are relatively time- consuming, re-irreversible infarction. If the PWI abnormality is larger than quiring 15 to 20 minutes of imaging time, even with limited the area of restricted diffusion ( diffusion/ perfusion mis- stroke imaging protocols, and they are generally less avail-match), then the region with normal diffusion, but abnormal able and more expensive than CT ( 1). It is often difficult to perfusion, is called " the ischemic penumbra" ( Fig. 3). If flow adequately screen acutely ill stroke patients for contra-is not restored to the penumbra, the diffusion abnormality indications to MRI and difficult for such patients to coop-will presumably increase in size to include much of the area erate with the relatively protracted examination. Additionally, of perfusion abnormality ( 1,20- 22). More recent studies, monitoring patients in the MR scanning environment can however, have shown a more complicated process. The be problematic. For most clinical uses, relative, not abso-diffusion changes may be partially reversible in patients lute, quantitative perfusion maps can be obtained with MRI undergoing successful recanalization with intra- arterial techniques. However, this method permits imaging of the thrombolysis such that the penumbra includes not only the entire brain, gives information not only on perfusion, but area of diffusion/ perfusion mismatch, but also part of the also on the status of tissue viability via DWI and can assess area of restricted diffusion ( 24- 26). There have also been vacular patency if MRA is added. No ionizing radiation is reports of initially normal diffusion in patients presenting used and there are usually fewer contraindications to gad-within 4 hours of symptom onset who eventually went on to olinium contrast agents than to iodinated contrast, documented infarction. Thus, negative DWI does not exclude impending infarction. However, several of these pa- POSITRON EMISSION TOMOGRAPHY tients had abnormal perfusion parameters at the time of PET studies using 15oxygen tracers have often been initial imaging ( 27,28). Also, there is no consensus as to considered the gold standard in the assessment of cerebral which perfusion parameter or combination of parameters perfusion ( 35). Quantitative values can be obtained for CBF, best defines the penumbra, although a decreased CBV CB\ J oxygen extraction fraction ( OEF), and cerebral meta-likely indicates tissue that is destined to infarct ( 1). No bolic rate for oxygen consumption ( CMR02), providing an studies have been performed to assess whether any assessment of energy metabolism as well as cerebral per-perfusion or diffusion parameters indicate risk of hemor- fusion ( 35). PET studies have defined the penumbra as an rhage with thrombolysis. area with severely reduced CBF, increased OEF ( more than Cerebral Perfusion Imaging J Neuro- Ophthalmol, Vol. 25, No. 4, 2005 0.7; normal, 0.4), and relatively preserved CMR02 ( more than 1.4 mL • 100 g_ 1 • min- 1 = 60 | Jimol • 100 g_ 1 • muT1), a pattern called " misery perfusion" ( 35,36). Although the results vary somewhat among authors, the penumbra likely lies between CBF values of approximately 12 mL- 100 g_ 1 • min- 1 and 22 mL • 100 g_ 1 • min- 1. Some studies have indicated that tissue with CBF of as low as 7 mL- 100 g_ 1 - min- 1 may recover. In PET studies, penumbric tissue has been identified up to 48 hours after symptom onset ( 35,36). PET studies using tracers other than 15oxygen, such as llC- flumazenil ( FMZ) or 18fluoromisonidazole, may be helpful in distinguishing irreversibly damaged tissue from potentially salvageable tissue ( 37,38). Although PET studies have shown improved flow in response to thrombolytic therapy, PET has not been used to help select patients for thrombolysis or assess the risk of hemorrhage from such therapy ( 39). PET has proven to be more useful in the assessment of patients with known cerebrovascular disease who have not yet had complete infarction, particularly those with carotid occlusion. Up to 60% of patients with carotid occlusion may be asymptomatic because of adequate collateral circulation. PET studies in patients with symptomatic carotid or middle cerebral artery occlusion have shown that an increased OEF is an independent risk factor for stroke ( 15). It is still unknown whether improving this parameter through revascularization procedures would lead to a decrease in stroke risk ( 15,40). PET has also been used in a wide variety of additional clinical settings, including SAH and carotid BTO. It may be helpful in assessing impaired oxygen metabolism in patients with post- SAH vasospasm ( 41). PET imaging obtained during temporary carotid BTO may be helpful in predicting the adequacy of flow after permanent occlusion ( 42). Although PET is the oldest and best validated perfusion imaging technique, its use in routine clinical settings is limited. Many hospitals lack PET imaging facilities. Even if these facilities are available, they are rarely available after hours. PET is a complex imaging technique requiring multi- tracer applications and a cyclotron to produce the radiotracers ( 35). There is exposure to significant radiation doses ( 43). Quantitative results require arterial blood gas sampling which is contraindicated in patients receiving thrombolytic therapy ( 35). SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY SPECT CBF imaging is obtained using 99mTc as the radioisotope attached to hexamethylpropyleneamine ( HMPAO) or ethyl cysteinate dimer ( ECD) ( 1). These tracers cross the blood- brain barrier and localize in the brain tissue in proportion to blood flow at the time of injection. Imaging can be performed up to several hours after injection ( 44). With this semiquantitative technique, activity in an infarcted area is compared with a presumably normal area in the contralateral cerebral hemisphere or to the presumably unaffected cerebellum ( 1). SPECT is a well-established technique with sensitivity of 61%- 74% and a specificity of 88%- 98% to abnormal perfusion in acute stroke ( 45). It is better at detecting cortical infarcts than smaller infarcts involving deep perforating vessels. The threshold of relative CBF between infarcted and viable tissue is between 0.48 and 0.52 in patients not receiving thrombolytic therapy ( 45,46). SPECT studies evaluating perfusion in patients undergoing thrombolytic therapy indicate that assessing the degree of perfusion of ischemic tissue may be a more useful guide to treatment than the duration of symptoms. Among patients receiving intraarterial thrombolysis, relative CBF thresholds for reversibility of ischemia and for hemorrhage after such therapy were 0.55 and 0.35, respectively, in one study ( 47). SPECT has been used in conjunction with an acet-azolamide challenge to assess hemodynamic impairment in patients with chronic cerebrovascular disease. This requires performing two examinations separated by one or more days and assumes that CBF does not change significantly between the two tests. Relative ( but not absolute) flow values can be obtained. Ratios of CBF that indicate an increased risk of stroke have not been denned ( 1). Likewise, SPECT has been used during carotid BTO, with the radiotracer being injected while the balloon is inflated. Imaging can be obtained within several hours to document the relative CBF at the time of balloon occlusion. However, no threshold value of lowered CBF indicating inadequate collateral circulation has been determined ( 1). There have been limited reports of the use of SPECT in patients with possible post- SAH vasospasm ( 1). SPECT imaging is relatively accessible; most large radiology departments have the appropriate hardware and software ( 1). But it may be difficult to acquire the kit required to make the injected compound on an emergent basis ( 1,45). A low resolution technique compared with MRI and CT, SPECT provides little anatomic detail so that it is necessary to correlate the findings with a higher- resolution imaging modality. Because it is only a semiquantitative technique, it requires comparison to the contralateral " normal" hemisphere ( 1). Relative CBF is the only parameter that can be measured with this technique. XENON COMPUTED TOMOGRAPHY Xenon ( Xe) is an inert gas that is soluble in both water and lipid, x- ray attenuation by Xe is similar to that of iodine, so Xe can be used as a contrast agent in conjunction with CT ( XeCT) ( 1). The gas dissolves rapidly in blood after inhalation and diffuses rapidly into the brain ( 1,48). 317 J Neuro- Ophthalmol, Vol. 25, No. 4, 2005 Hoeffner Diffusion into the brain is determined by blood flow and solubility of the Xe within different brain compartments ( 48). Patients inhale a mixture of 26%- 32% Xe mixed with 02 over a period of approximately 4.3 minutes. Processing of the data allows generation of CBF maps, from which quantitative data can be extracted ( 1,48). Multiple studies have validated the accuracy of CBF values obtained with XeCT ( 49,50). In acute ischemia, CBF values greater than 20 mL • 100 g_ 1 • mkT1 are associated with sustained viability and reversible neurologic deficit; CBF values less than 10 mL • 100 g_ 1 • mkU1 correlate with eventual infarct volume. CBF between 10 - 20 mL- 100 g_ 1 mkU1 has been associated with neurologic deficits that have been reversible with aggressive revascularization procedures or with infarction if no revascularization occurred ( 51,52). A CBF of less than 15 mL • 100 g_ 1 min- 1 has been associated with an increased risk of edema and brain herniation, as well as hemorrhage after thrombolytic therapy ( 53,54). Paired XeCT studies obtained before and after an acetazolamide vasodilatory stimulus have been used to assess hemodynamic impairment in patients with chronic ischemia. Decreased vascular response to the acetazolamide indicates pre- existing vasodilatation and loss of normal autoregulatory vascular reserve ( Fig. 4). A decrease in CBF values after acetazolamide administration indicates a high risk of subsequent stroke ( 16,17,55). XeCT has also been used to identify the presence of ischemia ( denned as CBF less than 20 mL • 100 g~ x • min~ v) in patients with post- SAH vasospasm and has been used to document improved CBF after medical or endovascular therapy ( 56- 58). In the setting of carotid BTO, XeCT has been used to help identify patients who clinically pass the BTO but have CBF less than 30 mL • 100 g_ 1 - min- 1, placing them at increased risk of stroke ( 59- 62). Adding acetazolamide may help identify patients who exhaust their cerebrovascular reserve during the BTO ( 62). XeCT is not only a quantitative method of CBF analysis, but this technique is standardized for a given CT system and between different systems ( 1). Being an inert gas, Xe cannot cause allergic reactions, but at the concentration used for XeCT, it can cause mild sedation, sensory changes, and nausea ( 63). Despite the widespread availability of standard CT scanners, the relatively low cost of the additional equipment needed to perform XeCT examinations, and the extensive medical literature pertaining to its role in evaluating cerebrovascular diseases, this technique has not had extensive use in the United States ( 1,45). Patients with neurologic impairment often cooperate poorly for the examination, during which they must inhale the Xe gas through a face mask or mouthpiece. Patient motion can produce artifacts that hamper interpretation ( 1). CBF is the only parameter that can be measured with XeCT ( 1). Currently there is no commercial supplier of medical grade Xe approved by the Food and Drug Administration; use of the agent is available only under Investigational New Drug authorization ( 1). CONCLUSION Among the many perfusion imaging techniques, PWI and PCT are the two most frequently used in clinical practice. PCT can be performed rapidly and has the potential for wide availability, whereas PWI is a more time- consuming procedure and less readily available, but when used in FIG. 4. Chronic left MCA ischemia as demonstrated by XeCT. ( A) Axial XeCT shows minimally diminished CBF in the left hemisphere ( arrows) compared with the right hemisphere. ( B) After acetazolamide administration, the axial XeCT CBF map shows a normal increase in CBF in all territories except that of the left MCA, where the CBF decreases, compatible with a steal phenomenon from maximally dilated left MCA vasculature. ( C) After a left external carotid to internal carotid artery bypass, the axial XeCT CBF map demonstrates more symmetrical flow between the hemispheres than in ( A). ( D) After acetazolamide administration, the axial XeCT CBF map now shows a normal increase in CBF in all territories, indicating restoration of vascular reserve in the left MCA territory. 318 © 2005 Lippincott Williams & Wilkins Cerebral Perfusion Imaging J Neuro- Ophthalmol, Vol. 25, No. 4, 2005 conjunction with DWI, it may provide a relatively simple means of differentiating ischemic penumbra from ischemic core. The use of older and more validated PWI techniques is hampered by their limited availability. REFERENCES 1. Latchaw RE, Yonas H, Hunter GJ, et al. Guidelines and recommendations for perfusion imaging in cerebral ischemia: a scientific statement for healthcare professionals by the writing group on perfusion imaging, from the Council on Cardiovascular Radiology of the American Heart Association. Stroke 2003; 34: 1084- 10. 2. Hoeffner EG, Case I, Jain R, et al. Cerebral perfusion CT: technique and clinical applications. Radiology 2004; 231: 632^ 4. 3. The National Institute of Neurological Disorders and Stroke rt- PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N EnglJ Med 1995; 333: 1581- 7. 4. Koenig M, Klotz E, Luka B, et al. Perfusion CT of the brain: diagnostic approach for early detection of ischemic stroke. Radiology 1998; 209: 85- 93. 5. Von Kummer R, Allen KL, Holle R, et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology 1997; 205: 327- 33. 6. Nabavi DG, Cenis A, Craen RA, et al. CT assessment of cerebral perfusion: experimental validation and initial clinical experience. Radiology 1999; 213: 141- 9. 7. Eastwood JD, Lev MH, Provenzale JM. Perfusion CT with iodinated contrast material. AJR Am J Roentgenol 2003; 180: 3- 12. 8. Tomandl BF, Klotz E, Handschu R, et al. Comprehensive imaging of ischemic stroke with multisection CT. Radiographics 2003; 23: 565- 92. 9. Eastwood JD, Lev MH, Azhari T, et al. CT perfusion scanning with deconvolution analysis: pilot study in patients with acute middle cerebral artery stroke. Radiology 2002; 222: 227- 36. 10. Wintermark M, Reichhart M, Thiran JP, et al. Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann Neurol 2002; 51: 417- 32. 11. Lee T, Fox AJ, Sahlas D, et al. CT perfusion in acute stroke: functional indicators of tissue viability [ abstract]. American Society of Neuroradiology Proceedings 2004: 15. 12. Schaefer PW, Roccatagliata L, Ledezma CJ, et al. Assessment of tissue viability with quantitative ct perfusion in acute ischemic stroke patients treated with intraarterial thrombolysis [ abstract]. American Society of Neuroradiology Proceedings 2004: 16- 17. 13. Eastwood JD, Alexander MJ, Petrella JR, et al. Dynamic CT perfusion imaging with acetazolamide challenge for the preproce-dural evaluation of a patient with symptomatic middle cerebral artery occlusive disease. AJNR Am J Neuroradiol 2002; 23: 285- 7. 14. Hughes MA, Hoeffner EG, Mukherji SK, et al. Use of perfusion CT in conjunction with the acetazolamide challenge test in evaluating patients with chronic cerebral ischemia. Radiologic Society of North America Scientific Assembly and Annual Meeting Program, 2003: 786. 15. Derdeyn CP, Grubb RL Jr, Powers WJ. Cerebral hemodynamic impairment: methods of measurement and association with stroke risk. Neurology 1999; 53: 251- 9. 16. Yonas H, Smith HA, Durhan SR, et al. Increased stroke risk predicted by compromised cerebral blood flow reactivity. JNeurosurg 1993; 79: 483- 9. 17. Webster MW, Makaroun MS, Steed DL, et al. Compromised cerebral blood flow reactivity is a predictor of stroke in patients with symptomatic carotid artery occlusive disease. J Vase Surg 1995; 21: 338- 45. 18. Nabavi DG, LeBlanc LM, Baxter B, et al. Monitoring cerebral perfusion after subarachnoid hemorrhage using CT. Neuroradiology 2001; 43: 7- 16. 19. Jain R, Hoeffner E, Gandhi D, et al. Perfusion ct after subarachnoid hemorrhage: utility as a screening tool to determine which patients should proceed to angiography [ abstract]. American Society of Neuroradiology Proceedings 2003: 26. 20. Sorensen AG, Buonanno FS, Gonzalez RG, et al. Hyperacute stroke: evaluation with combined multisection diffusion- weighted and herno-dynamically weighted echo- planar MR imaging. Radiology 1996; 199: 391^ 0. 21. Karonen JO, Vanninen RL, Liu Y, et al. Combined diffusion and perfusion MRI with correlation to single- photon emission CT in acute ischemic stroke: ischemic penumbra predicts infarct growth. Stroke 1999; 30: 1583- 90. 22. Karonen JO, Liu Y, Vanninen RL, et al. Combined perfusion- and diffusion- weighted MR imaging in acute ischemic stroke during the 1st week: a longitudinal study. Radiology 2000; 217: 886- 94. 23. Sunshine JL, Tarr RW, Lanzieri CF, et al. Hyperacute stroke: ultrafast MR imaging to triage patients prior to therapy. Radiology 1999; 212: 325- 32. 24. Kidwell CS, Saver JL, Mattiello J, et al. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/ perfusion magnetic resonance imaging. Ann Neurol 2000; 47: 462- 9. 25. Grant PE, He J, Halpern EF, et al. Frequency and clinical context of decreased apparent diffusion coefficient reversal in the human brain. Radiology 2001; 221: 43- 50. 26. Schaefer PW, Hassankhani A, Putman C, et al. Characterization and evolution of diffusion MR imaging abnormalities in stroke patients undergoing intra- arterial thrombolysis. AJNR Am J Neuroradiol 2004; 25: 951- 7. 27. Lefkowitz D, LaBenz M, Nudo SR, et al. Hyperacute ischemic stroke missed by diffusion- weighted imaging. AJNR Am J Neuroradiol 1999; 20: 1871- 5. 28. Wang PY, Barker PB, Wityk RJ, et al. Diffusion- negative stroke: a report of two cases. AJNR Am J Neuroradiol 1999; 20: 1876- 80. 29. Kluytmans M, van der Grond J, Viergever MA. Gray matter and white matter perfusion imaging in patients with severe carotid artery lesions. Radiology 1998; 209: 675- 82. 30. Lythgoe DJ, Ostergaard L, Williams SC, et al. Quantitative perfusion imaging in carotid artery stenosis using dynamic susceptibility contrast- enhanced magnetic resonance imaging. Magn Reson Imaging 2000; 18: 1- 11. 31. Kikuchi K, Murase K, Miki H, et al. Measurement of cerebral hemodynamics with perfusion- weighted MR imaging: comparison with pre- and post- acetazolamide 133Xe- SPECT in occlusive carotid disease. AJNR Am J Neuroradiol 2001; 22: 248- 54. 32. Mukherjee P, Kang HC, Videen TO, et al. Measurement of cerebral blood flow in chronic carotid occlusive disease: comparison of dynamic susceptibility contrast perfusion MR imaging with positron emission tomography. AJNR Am J Neuroradiol 2003; 24: 862- 71. 33. Rordorf G, Koroshetz WJ, Copen WA, et al. Diffusion- and perfusion- weighted imaging in vasospasm after subarachnoid hemorrhage. Stroke 1999; 30: 599- 605. 34. Michel E, Liu H, Remley KB, et al. Perfusion MR neuroimagining in patients undergoing balloon test occlusion of the internal carotid artery. AJNR Am J Neuroradiol 2001; 22: 1590- 6. 35. Heiss WD. Ischemic penumbra: evidence from functional imaging in man. J Cereb Blood Flow Metab 2000; 20: 1276- 93. 36. Marchal G, Beaudouin V, Roiux P, et al. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: a correlative PET- CT study with voxel- based data analysis. Stroke 1996; 27: 599- 606. 37. Heiss WD, Grond M, Thiel A, et al. Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. Stroke 1998; 29: 454- 61. 38. Read SJ, Hirano T, Abbott DF, et al. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F- fluoromisonifazole. Neurology 1998; 51: 1617- 21. 39. Heiss WD, Grond M, Thiel A, et al. Tissue at risk of infarction rescued by early reperfusion: a positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke. J Cereb Blood Flow Metab 1998; 18: 1298- 307. 40. Powers WJ, Zazulia AR. The use of positron emission tomography in cerebrovascular disease. Neuroimaging Clin NAm 2003; 13: 741- 58. 319 J Neuro- Ophthalmol, Vol. 25, No. 4, 2005 Hoeffner 41. Herholts K, Heiss WD. Positron emission tomography in clinical neurology. Mol Imaging Biol 2004; 6: 239- 6. 42. Brunberg JA, Frey KA, Horton JA, et al. [ 150] H20 positron emission tomography determination of cerebral blood flow during balloon test occlusion of the internal carotid artery. AJNR Am J Neuroradiol 1994; 15: 725- 32. 43. Markus HS. Cerebral perfusion and stroke. J Neurol Neurosurg Psychiatry 2004; 75: 353- 61. 44. Grotta JC. Alexandrov AV tPA- associated reperfusion after acute stroke demonstrated by SPECT. Stroke 1998; 29: 429- 32. 45. Latchaw RE. Cerebral perfusion imaging in acute stroke. J Vase Interv Radiol 2004; 15: S29^ 6. 46. Shimosegawa E, Hatazawa J, Inugami A, et al. Cerebral infarction within six hours of onset: prediction of completed infarction with technetium- 99m- HMPAO SPECT. JNucl Med 1994; 35: 1097- 103. 47. Ueda T, Sakaki S, Yuh WT, et al. Outcome in acute stroke with successful intra- arterial thrombolysis and predictive value of initial single- photon emission- computed tomography. J Cereb Blood Flow Metab 1999; 19: 99- 108. 48. Pindzola RR, Yonas H. The xenon- enhanced computed tomography cerebral blood flow method. Neurosurgery 1998; 43: 1488- 92. 49. DeWitt DS, Fatouros PP, Wist AO, et al. Stable xenon versus radiolabeled microsphere cerebral blood flow measurements in baboons. Stroke 1989; 20: 1716- 23. 50. Yonas H, Darby JM, Marks EC, et al. CBF measured by Xe- CT: approach to analysis and normal values. J Cereb Blood Flow Metab 1991; 11: 716- 25. 51. Firlik AD, Rubin G, Yonas H, et al. Relationship between cerebral blood flow and neurologic deficit resolution in acute ischemic stroke. Neurology 1998; 51: 177- 82. 52. Firlik AD, Kaufmann AM, Wechsler LR, et al. Quantitative cerebral blood flow determinations in acute ischemic stroke: relationship to computed tomography and angiography. Stroke 1997; 28: 2208- 13. 53. Firlik AD, Yonas H, Kaufmann AM, et al. Relationship between cerebral blood flow and the development of swelling and life-threatening herniation in acute ischemic stroke. J Neurosurg 1998; 89: 243- 9. 54. Goldstein S, Yonas H, Gebel JM, et al. Acute cerebral blood flow as a predictive physiologic marker for symptomatic hemorrhagic conversion and clinical herniation after thrombolytic therapy. Stroke 2000; 31: 275. 55. Nariai T, Suzuki R, Hirakawa K, et al. Vascular reserve in chronic cerebral ischemia measured by the acetazolamide challenge test: comparison with positron emission tomography. AJNR Am J Neuroradiol 1995; 16: 563- 70. 56. Yonas H, Sekhar L, Johnson DW, et al. Determination of irreversible ischemia by xenon- enhanced computed tomographic monitoring of cerebral blood flow in patients with symptomatic vasospasm. Neurosurgery 1989; 24: 368- 72. 57. Firlik AD, Kaufmann AM, Jungreis CA, et al. Effect of transluminal angioplasty on cerebral blood flow in the management of symptomatic vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 1997; 86: 830- 9. 58. Firlik KS, Kaufmann AM, Firlik AD, et al. Intra- arterial papaverine for the treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Surg Neurol 1999; 51: 66- 74. 59. Sen C, Sekhar LN. Direct vein graft reconstruction of the cavernous, petrous, and upper cervical internal carotid artery: lessons learned from 30 cases. Neurosurgery 1992; 30: 732^ 3. 60. Mathis JM, Barr JD, Horton JA. Therapeutic occlusion of major vessels, test occlusion and techniques. Neurosurg Clin NAm 1994; 5: 393^ 01. 61. Mathis JM, Barr JD, Jungreis CA, et al. Temporary balloon occlusion of the internal carotid artery: experience in 500 cases. AJNR Am J Neuroradiol 1995; 16: 749- 54. 62. Okudaira Y, Arai H, Sato K. Cerebral blood flow alteration by acetazolamide during carotid balloon occlusion: parameters reflecting cerebral perfusion pressure in the acetazolamide test. Stroke 1996; 27: 617- 21. 63. Johnson DW, Stringer WA, Marks MP, et al. Stable xenon CT cerebral blood flow imaging: rationale for and role in clinical decision making. AJNR Am J Neuroradiol 1991; 12: 201- 13. 320 © 2005 Lippincott Williams & Wilkins [VBheadinjury] |